Business Wire

Pingo Doce Sets New Standard for AI-Driven Merchandising with SymphonyAI—and Raises the Bar for CPG Collaboration

14.10.2025 06:06:00 CEST | Business Wire | Press Release

Share

Pingo Doce is moving fast to redefine merchandising with AI—replacing static reports with real-time, prescriptive insights that fuel sharper execution and stronger supplier alignment. The Portuguese retailer is part of Jerónimo Martins, one of Europe’s largest food retailers with over 5,700 stores across Portugal, Poland, and Colombia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013626268/en/

Instead of static dashboards or flat-file reports, suppliers now get direct access to actionable intelligence. CPG partners can run dynamic “what-if” scenarios, optimize promotions and assortments, and see projected revenue impacts—collaborating in real time with Pingo Doce category teams.

Powered by SymphonyAI’s CINDE Connected Retail platform, Pingo Doce is combining POS, assortment and shelf data into a single intelligent layer. The result: a modern monetizable insights platform that delivers next-best actions for both internal teams and CPG partners—store by store, SKU by SKU.

“We’re not just improving how we operate—we’re transforming how we collaborate,” said Francisco Soure, Executive Director of Digital & Innovation at Pingo Doce. “SymphonyAI gives our teams and our suppliers a shared view of what’s happening, and the AI-driven actions to make better decisions together—faster.”

This move marks a bold modernization of Pingo Doce’s merchandising and CPG collaboration to date, bringing AI and increased interactivity to its insights-as-a-service model. Pingo Doce is leveraging AI to bring speed, precision, and the ability to make smarter, faster decisions in lockstep with CPG partners—and CINDE will deliver on all three.

CINDE will enable executives to bypass analytics bottlenecks with natural-language queries and instant answers. Category teams will receive clear recommendations to support decision making in adjusting promotions and assortments. CPG partners, for the first time, could explore store-level performance in real time—deepening alignment and accelerating joint growth.

“Pingo Doce isn’t just adopting AI—they’re wielding it as competitive leverage,” said Manish Choudhary, President, SymphonyAI Retail-CPG. “They’re showing what bold retail innovation looks like: real-time insights, shared intelligence, and faster action across every link in the value chain.”

About Pingo Doce

Pingo Doce is part of the Jerónimo Martins group, with over 230 years of know-how in the food business, the Jerónimo Martins Group operates more than 5,700 stores in Portugal, Poland, Colombia and Slovakia. https://www.jeronimomartins.com/en/

About SymphonyAI

SymphonyAI builds vertical AI applications that help enterprises tackle their most complex, high-value challenges—like stopping financial crime, improving store performance, and boosting manufacturing efficiency. Trusted by more than 2000 enterprise customers across the world, including 200 of the top financial institutions, top 25 CPGs, and many of the world’s largest grocers and industrial manufacturers, SymphonyAI delivers domain-trained applications and pre-built agents, ready to work on day one. Learn more at www.symphonyai.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251013626268/en/

Contacts

Media Contact
SymphonyAI
Media@Symphonyai.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye